研究单位：[1]Boehringer Ingelheim[2]La Mesa Cardiac Center[3]Long Beach Center for Clinical Research[4]Tongji Hospital, Tongji University
研究目的：
The aim of the study is to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction.
